Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis
Source abstract
Abstract
In this study, we identified hsa_circ_0051240 was significantly increased in ovarian cancer (OC) tissues. Our results indicated that silencing of hsa_circ_0051240 inhibited OC cell proliferation, migration and invasion in vitro, and also prevented OC tumour formation in vivo. In addition, the inhibitory effects by blockage of hsa_circ_0051240 could be attenuated by the miR-637 inhibitor. Furthermore, we also identified that hsa_circ_0051240 act as a sponge of miR-637, and miR-637 directly targeted KLK4 mRNA in OC cells. Altogether, hsa_circ_0051240 promotes OC cell proliferation, migration and invasion through inhibiting the miR-637/KLK4 axis. Therefore, these results demonstrated that the hsa_circ_0051240/miR-637/KLK4 axis might serve as a therapeutic target for OC treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Gynecology, Harbin Medical University Cancer Hospital
Department of Cell Biology, Harbin Medical University
Funding
National Natural Science Foundation of China
References (29)
Show source-provided references
1. 10.1371/journal.pone.019635110.1371/journal.pone.0196351 ↗
2. 10.1016/S0140-6736(09)61338-610.1016/S0140-6736(09)61338-6 ↗
3. 10.1016/j.tig.2016.03.00210.1016/j.tig.2016.03.002 ↗
4. 10.1371/journal.pone.003073310.1371/journal.pone.0030733 ↗
5. 10.1186/s12943-018-0827-810.1186/s12943-018-0827-8 ↗
6. 10.1016/j.bbagrm.2015.07.00710.1016/j.bbagrm.2015.07.007 ↗
7. 10.1007/s40139-017-0123-010.1007/s40139-017-0123-0 ↗
8. 10.1016/j.gde.2018.01.00110.1016/j.gde.2018.01.001 ↗
9. 10.1073/pnas.051115510310.1073/pnas.0511155103 ↗
10. 10.1002/hep.2459510.1002/hep.24595 ↗
11. Li JX, Ding XM, Han S, et al. Mir-637 inhibits the proliferation of cholangiocarcinoma cell QBC939 through interfering CTSB expression. Eur Rev Med Pharmacol Sci. 2018;22:1265–1276.
12. 10.1016/j.yexcr.2018.01.02610.1016/j.yexcr.2018.01.026 ↗
13. 10.1091/mbc.e11-04-035610.1091/mbc.e11-04-0356 ↗
14. 10.12659/MSM.89725410.12659/MSM.897254 ↗
15. 10.1038/onc.2014.41910.1038/onc.2014.419 ↗
16. 10.1006/meth.2001.126210.1006/meth.2001.1262 ↗
17. 10.1016/j.jbiotec.2016.09.01110.1016/j.jbiotec.2016.09.011 ↗
18. 10.1016/j.canlet.2017.03.02710.1016/j.canlet.2017.03.027 ↗
19. 10.1038/nature0914410.1038/nature09144 ↗
20. 10.1016/j.cell.2011.09.02810.1016/j.cell.2011.09.028 ↗
21. 10.1016/j.cell.2011.07.01410.1016/j.cell.2011.07.014 ↗
22. 10.1038/nature1199310.1038/nature11993 ↗
23. 10.1038/cr.2017.13610.1038/cr.2017.136 ↗
24. 10.1038/ncomms1121510.1038/ncomms11215 ↗
25. 10.18632/oncotarget.858910.18632/oncotarget.8589 ↗
26. 10.1038/nrd453410.1038/nrd4534 ↗
27. Hannu K, Johanna M, Ulf-Håkan S. KLK-targeted therapies for prostate cancer. Ejifcc. 2014;25:207–218.
28. 10.1016/j.canlet.2012.11.03610.1016/j.canlet.2012.11.036 ↗
29. 10.1016/j.molonc.2013.09.00310.1016/j.molonc.2013.09.003 ↗